Quick Answer
Pacira BioSciences, Inc. reported Stockholders Equity of $693.11 million for the year ending 2025.
- Pacira BioSciences, Inc. showed a decrease of -11.0% in Stockholders Equity from 2024 to 2025.
- This data is from Pacira BioSciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $94.51 million | Q3 2012: $80.45 million | Q1 2013: $69.79 million | Q2 2013: $59.14 million | Q3 2013: $49.12 million | Q1 2014: $35.71 million | Q2 2014: $147.97 million | Q3 2014: $155.07 million | Q1 2015: $184.02 million | Q2 2015: $195.28 million | Q3 2015: $209.01 million | Q1 2016: $226.17 million | Q2 2016: $228.35 million | Q3 2016: $214.15 million | Q1 2017: $270.63 million | Q2 2017: $261.05 million | Q3 2017: $264.80 million | Q1 2018: $278.52 million | Q2 2018: $290.51 million | Q3 2018: $301.27 million | Q1 2019: $327.52 million | Q2 2019: $341.65 million | Q3 2019: $346.16 million | Q1 2020: $374.04 million | Q2 2020: $388.15 million | Q3 2020: $584.69 million | Q1 2021: $650.82 million | Q2 2021: $687.17 million | Q3 2021: $718.60 million | Q1 2022: $709.58 million | Q2 2022: $756.64 million | Q3 2022: $770.12 million | Q1 2023: $768.04 million | Q2 2023: $807.98 million | Q3 2023: $831.55 million | Q1 2024: $892.16 million | Q2 2024: $879.28 million | Q3 2024: $749.58 million | Q1 2025: $798.54 million | Q2 2025: $757.77 million | Q3 2025: $727.21 million.
- Over the full 14 years of available data (2012 to 2025), Pacira BioSciences, Inc.'s Stockholders Equity has grown by 952.5%.
- Historical annual values: Fiscal year 2025: $693.11 million | Fiscal year 2024: $778.35 million | Fiscal year 2023: $870.13 million | Fiscal year 2022: $775.01 million | Fiscal year 2021: $730.41 million | Fiscal year 2020: $619.69 million | Fiscal year 2019: $354.94 million | Fiscal year 2018: $321.23 million | Fiscal year 2017: $279.48 million | Fiscal year 2016: $218.98 million | Fiscal year 2015: $218.39 million | Fiscal year 2014: $171.15 million | Fiscal year 2013: $41.25 million | Fiscal year 2012: $65.86 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: